<DOC>
	<DOCNO>NCT00295425</DOCNO>
	<brief_summary>Psoriasis immuno-mediated skin disorder , affect 2-3 % population worldwide . For moderate-severe form psoriasis systemic immunosuppression treatment choice . This clinical trial initiate compare safety effectiveness mycophenolate mofetil cyclosporine A treatment psoriasis . Patients randomize receive either 2.5 mg/kg BW cyclosporine A 1 g bid mycophenolate mofetil . If six week decrease PASI score occures cyclosporine A dos increase 5 mg/kg BW additional six week . In arm mycophenolate mofetil increase 1 g tid additional six week .</brief_summary>
	<brief_title>CYA Versus MMF Treatment Moderate-Severe Psoriasis .</brief_title>
	<detailed_description>Not need .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>moderatetosevere psoriasis ( PASI Score equal greated 10 ) write informed consent female patient effective birth control psoriasis arthritis psoriasis palmoplantaris erythrodermic psoriasis druginduced psoriasis pregnancy previous treatment cyclosporine A mycophenolate mofetil pregnancy reduce liver function high blood pressure reduce kidney function severe viral bacterial infection 2 week vaccination innate acquire immunodeficiency severe neurologic psychiatric symptom participation trial reason voice treat physician</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2006</verification_date>
	<keyword>psoriasis</keyword>
	<keyword>randomize clinical trial</keyword>
	<keyword>cyclosporine A</keyword>
	<keyword>mycophenolate mofetil</keyword>
	<keyword>immunosuppression</keyword>
</DOC>